21 Responses

  1. Sysy
    Sysy January 3, 2011 at 6:03 am | | Reply

    Agreed. Totally, agreed.

  2. Tweets that mention » Just How Hot Are We for Inhalable Insulin? - DiabetesMine: the all things diabetes blog --

    [...] This post was mentioned on Twitter by DiabetesMine and JCampbell. JCampbell said: DiabetesMine: Just How Hot Are We for Inhalable Insulin? #diabetes [...]

  3. Richard
    Richard January 3, 2011 at 9:17 am | | Reply

    As far as I understood it the inhalible insulin is only available for short acting insulin, meaning that every diabetic who uses a long acting type of insulin is not free of injections anyway. And as far as I can tell, this is the majority of insulin using diabetics.
    Even if you use a pump instead of long acting, the idea of inhalable insulin is even more mute as you’re already attached to the pump anyway.

    As far as I’m concerned, not requiring needles is a silly argument in favor of inhalable insulin.

  4. Nyx
    Nyx January 3, 2011 at 11:52 am | | Reply

    I think for some people inhaled insulin would be a great option, big time if one is scared of needles and that is their big sticking point for not using insulin it would be helpful in that area. Though I am not sure how helpful it would be long term or for those who are type 1, maybe for type 2s it might be an option to a degree … guess well have to wait and see what happens.

    I vote for it though, if nothing else it would give those who like me are scared of needles a fighting change at getting diabetes under control better (I do take my needles as needed, but I still a scared of the needle and I still try and put it off, which isn’t good for me at all).

  5. Gary Jones
    Gary Jones January 3, 2011 at 11:56 am | | Reply

    Sometimes I understand why a lack of real information among bloggers causes people to make lousy decisions and lose money. People who have no understanding of how much difference this particular insulin would make in a diabetics life shouldn’t pretend to know about that difference. Beyond the drastically smaller size of inhaler and that there are no needles involved in the basal delivery, this insulin, IF indeed it is as safe as tests indicate, reacts at basically the same rate as insulin produced from a healthy pancreas. My daughter is diabetic 1 and when she gets “hi” it takes an hour and a half to feel better, let alone the damage being done to her organs and body. And somehow these self appointed geniuses make decisions with their money and wonder why they lose. Inhalation and absorption is the future, not needles and more needles. Along with a continuous glucose meter this insulin comes close to providing normality in a diabetics life. So take your money, mister smart investor and bet against something, about which you really have no insight. Dummies.

  6. Mike
    Mike January 3, 2011 at 5:06 pm | | Reply

    My Goodness Gary, are you behind all the other grouchy and defensive Afresa posts strewn all over the internet? It sounds interesting but if it’s that hard to talk about civilly, I have to wonder if there’s something up with it?
    I guess if there turns out to be a deployment advantage in that it works quickly or something, maybe there’d be an advantage. I’m sorry to hear about your daughter’s challenges with running “HI” too.

    I used to IV R which works a bit quicker than Afresa seems to promise but is, of course, highly hair-raising or even extremely dangerous. I have not figured out how to make the ‘log in my pump work that quickly yet but don’t have the same issues to deal with.

    Afresa seems very interesting but it seems odd that there would be flamewars breaking out about it? I think their strongest argument is that it works faster and doesn’t require measurement and carb counting. I’d be all over that but couldn’t give a hoot about needles. I am saving 6000 of them in my garage for a rainy day. Although my ‘research’ (sic, I don’t take notes…) suggests that old needles wear out even when they aren’t in use? :-(

  7. Will the FDA Approve Afrezza? · Corengi Blog

    [...] The FDA decided last week to wait another four weeks before determining whether or not to approve Afrezza, an inhalable form of insulin that is being developed by Mannkind Corp.  There’s some insightful analysis at [...]

  8. Ryan Luce
    Ryan Luce January 3, 2011 at 5:22 pm | | Reply

    This looks like a sound analysis. I’m hopeful that the FDA is able to approve – as it sounds like a great option for some – but it doesn’t seem like investors’ concerns should come into the mix as far as making the decision. More commentary here:

    1. Robert
      Robert August 28, 2012 at 11:41 pm | | Reply

      Hello im robert and i have been a diabetic for 33 yrs.I do not know much about the inhalable insulin but i hope it works out for everyone.Taking shots every day sucks for any one having to do it,especially the kids,the pump sucks because your always hooked to tubing and you always have to pay for many other things like batteries ,inserters ,tubing,reservoirs,i.v.prep,alcolhol,etc…the makers are making a killing off of the people needing this stuff to stay alive and they dont care about it.I am waiting to see a company that truly cares and will come out with something thats not going to cost you an arm and a leg after you buy it to maintain.I would hope something like the inhaled insulin or the oralynn spray would be the holy grail for us diabetics whether you are type 1 or type 2.I will still have to sit back and wait a few years after they come out to see if they really work and to see how safe they really are ,then i will take my chance.good luck to all and good nite !

  9. mcityrk
    mcityrk January 3, 2011 at 6:45 pm | | Reply

    The biggest questions I have are technical; i.e. 1] are the safety claims accurate or a time-bomb waiting to happen when a larger sampling size of patients takes up the technology and 2] are the claims for freedom from hypoglycemia going to hold up over long term usage. I have never understood the claimed mechanism that allows insulin inhaled into the lungs to be matched properly to glucose levels in the blood stream thus allowing the lungs to act as a surragate pancreas. This implies some sort of controlled storage and release ability in the lungs that I am unaware of. If anyone can shed technical light on this claim, I would love to hear more about it.

    As to investibility of MNKD, if you look at the 2/11 options after the next supposed decision time in late Januarty for the FDA, both sides are showing >30% premiums to purchase either puts or calls so it seems obvious that noone really knows how this decision breaks.

  10. jenny
    jenny January 3, 2011 at 8:17 pm | | Reply

    My little girl would rather inhale insulin than get a shot any day.
    Market this to parents of children who cry, fight back, bite, scream, run and hide, bruise, bleed are too little to understand and must be held down for shots.
    Adults may prefer pumps etc but KIDS HATE SHOTS. PERIOD.
    I’m hopeful this is approved for children soon.

  11. Natalie Sera
    Natalie Sera January 4, 2011 at 3:11 pm | | Reply

    As an asthmatic, I would never put anything into my lungs that is not absolutely necessary. So Afrezza is not for me (I love my pump, anyway).
    I’m not sure how the dosage of Afrezza works, but it might be a real help to Type 2′s who don’t need as precise a dosage as Type 1′s. Plus it would be a real boon to needle-phobics.
    As far as children, I don’t know whether it would work or not, because you have to time your inhalation with the press of whatever button releases the medication. A small child would probably not be able to do that. For an older child, it might be useful.
    Well, we’ll just have to wait and see. I think it’s a good thing to have more options, anyway.

  12. Andrew H.
    Andrew H. January 4, 2011 at 6:26 pm | | Reply

    I’ll stick with my syringes thank you. At least I know the exact dosage, no worries about tubes getting clogged, pens not dosing right, etc etc. An insulin inhaler would make me look like I just have asthma. Come on, I’m so awesome my pancreas couldn’t take it anymore!

    Besides, I think everyone is missing the fun joy of using the syringes – freaking people out in restaurants when you shoot up in front of them.

  13. Jan
    Jan January 5, 2011 at 3:50 am | | Reply

    Not at all interested in inhalable insulin. There is another product, Ora-lyn, which is sprayed into the buccal cavity of the mouth. Can’t imagine the taste……. but interested because Oralynn is supposed to be absorbed very quickly, unlike injected insulin. So may eliminate postprandial spikes quite nicely. And supposedly much safer than inhaled insulin.

  14. Troy
    Troy January 5, 2011 at 7:07 am | | Reply

    John Arditi Dropped his lawsuit it was not “Settled out of Court” There was no payment or action by the company, the 1 and only wrongful termination suit was DROPPED!

  15. kdroberts
    kdroberts January 5, 2011 at 7:10 am | | Reply

    I think in theory it’s a good idea but I don’t think the market is big enough to sustain this type of product for very long. Yes there are certain people who could greatly benefit from inhaled insulin but there are far more that are either concerned with side effects of long term use, how consistent dosing is or are just not really interested.

    Ever since I heard about what MannKind was doing a while back I’ve wondered if they are barking up the wrong tree with Afrezza, I guess well find out relatively soon.

  16. type1guy
    type1guy January 5, 2011 at 7:51 am | | Reply

    Jan ; spend some time to understand the pk profile of afrezza and orallyn; while you are at it, check the bioavailability; also find out how many trials were done for both products; it is never too late to know something

  17. mnkdfan
    mnkdfan January 5, 2011 at 10:15 am | | Reply


    1) regarding safety claims, Pfizer compiled 8 year data for patients using Exubera. They didn’t find any issue


    2) “are the claims for freedom from hypoglycemia going to hold up over long term usage”
    it is easier to explain the lower incidence of hypos by checking the PK profile of Afrezza Vs. RAA.

    Afrezza shuts off hepatic glucose secretion faster than RAA, and most of action is over in 4 hours. Humalog acts for 6 hours.

    Also read feedback from Afrezza trial participants

  18. Curefor Diabetes
    Curefor Diabetes January 9, 2011 at 6:02 pm | | Reply

    great website. very informative

  19. Curefor Diabetes
    Curefor Diabetes January 9, 2011 at 6:04 pm | | Reply

    Great website. Lots of information

  20. Diabetes: La tecnología que viene « RDi Press

    [...] Just How Hot Are We for Inhalable Insulin? ( [...]

Leave a Reply